Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.
Storey
Dawn J
DJ
Colvin
Lesley A
LA
Mackean
Melanie J
MJ
Mitchell
Rory
R
Fleetwood-Walker
Susan M
SM
Fallon
Marie T
MT
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000432:Methanol / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use; D010147:Pain Measurement / Q000187:drug effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D050053:TRPM Cation Channels / Q000819:agonists*
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D050053:TRPM Cation Channels; C425966:TRPM8 protein, human; D016190:Carboplatin; D017239:Paclitaxel; D000432:Methanol